导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.23% | 3223/4773 |
| 近一周 | -2.76% | 3015/5462 |
| 近一月 | -6.96% | 3682/5421 |
| 近一季 | 7.63% | 215/5209 |
| 近半年 | -2.99% | 2088/4920 |
| 近一年 | -16.19% | 3765/4366 |
| 近两年 | 16.03% | 2723/2954 |
| 近三年 | -12.29% | 2058/2253 |
| 成立以来 | -19.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.65% 2404/4961 |
-6.42% 3692/5312 |
- - |
- - |
| 2025 | 4.92% 3022/4813 |
0.68% 1790/3635 |
1.87% 2067/4076 |
16.21% 2695/4524 |
-11.97% 4223/4813 |
| 2024 | -12.36% 2374/3463 |
-10.68% 2367/2808 |
-9.11% 2321/3014 |
18.67% 964/3129 |
-9.03% 2897/3463 |
| 2023 | -10.72% 1326/2656 |
0.18% 1751/2280 |
-7.34% 1841/2385 |
-1.37% 510/2515 |
-2.48% 479/2655 |
| 2022 | -20.16% 941/2207 |
-12.55% 629/1919 |
0.25% 1572/2016 |
-16.46% 1459/2113 |
9.01% 242/2208 |
| 2021 | -10.86% 1097/1822 |
-3.17% 770/1255 |
14.02% 269/1330 |
-15.16% 1381/1466 |
-4.83% 1497/1822 |
| 2020 | 46.91% 202/1250 |
6.27% 45/1028 |
27.88% 122/1067 |
2.45% 1005/1164 |
5.53% 782/1184 |
| 2019 | 27.79% 532/1092 |
27.06% 362/754 |
-8.50% 595/804 |
5.11% 164/850 |
4.57% 797/918 |
| 2018 | -24.13% 317/834 |
- - |
- - |
- - |
-18.66% 657/691 |
| 2017 | 11.38% 295/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.51% 378/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证医药卫生(LOF)A VS. 长安沪深300非周期A(740101) |